Multimodal prognostic models and recent therapeutic advances

Affiliations

¹ Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy. Electronic address: andrea.minervini@unifi.it.
² Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy.

Free article

Comment

Andrea Minervini et al. Lancet Digit Health. 2023 Aug.

Free article

. 2023 Aug;5(8):e482-e483.

doi: 10.1016/S2589-7500(23)00111-5. Epub 2023 Jun 29.

¹ Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy. Electronic address: andrea.minervini@unifi.it.
² Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy.

No abstract available

Conflict of interest statement

We declare no competing interests.

Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study.
Gui CP, Chen YH, Zhao HW, Cao JZ, Liu TJ, Xiong SW, Yu YF, Liao B, Cao Y, Li JY, Huang KB, Han H, Zhang ZL, Chen WF, Jiang ZY, Gao Y, Han GP, Tang Q, Ouyang K, Qu GM, Wu JT, Guo JP, Li CX, Li PX, Liu ZP, Hsieh JT, Cai MY, Li XS, Wei JH, Luo JH. Gui CP, et al. Lancet Digit Health. 2023 Aug;5(8):e515-e524. doi: 10.1016/S2589-7500(23)00095-X. Epub 2023 Jun 29. Lancet Digit Health. 2023. PMID: 37393162